Loading...

RLYB RALLYBIO CORP Product Launches 8-K Filing

RLLY

RLYB

RALLYBIO CORP

(RLYB)

2025 8-K

Show Summary

Summary

Asset Acquisitions

Financial Statements

Product Discontinuation

Stock Sale Amendment

Financial Results

Nasdaq Notification

Financial Results

Director Resignation

Financial Results Announcement

Resignation of Executive Ch...

Annual Meeting of Shareholders

Earnings Reports

Collaboration Agreement and...

Financial Results Announcement

Workforce Reduction and Est...

Phase 1 Data Announcement

Earnings Reports

Earnings Reports

Management Changes

Annual Meeting Results

Earnings Reports

Financial Results and Clini...

Appointment of New Chief Fi...

External Links:

On April 8, 2025, Rallybio Corporation announced the discontinuation of its RLYB212 program for preventing fetal and neonatal alloimmune thrombocytopenia due to Phase 2 clinical trial data.

AI Assistant

RALLYBIO CORP

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.